Anh Tu Nguyen - Feb 25, 2025 Form 3 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: Chief Medical Officer
Signature: /s/ Beth Hecht, Attorney-in-Fact
Stock symbol: XERS
Transactions as of: Feb 25, 2025
Transactions value $: $0
Form type: 3
Date filed: 3/7/2025, 04:11 PM
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	XERS	Common Stock						300K	Feb 25, 2025	Direct	F1
holding	XERS	Common Stock						3.71K	Feb 25, 2025	By IRA	F2
holding	XERS	Common Stock						3.5K	Feb 25, 2025	By children's IRA	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	XERS	Stock Appreciation Right							Feb 25, 2025	Common Stock	150K	$3.76	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F2	The shares were acquired through a custodial account established for the Reporting Person's children for which the Reporting Person serves as a custodian.
F3	This stock appreciation right granted under the Company's 2018 Stock Option and Incentive Plan will vest in full on the second anniversary of the February 24, 2025 grant date, subject to continued service with the company through the vesting date.
F4	Upon exercise, the stock appreciation right will be settled in cash.

Remarks:

Chief Medical Officer